Boardroom Alpha
Start trial
10-K primary document
RNTX · Annual Report (Form 10-K) · Filed March 26, 2026

Rein Therapeutics Inc — 10-K exhibit

rntx-ex23_2.htm
Rein Therapeutics Inc on Boardroom Alpha
EX-23.2

Exhibit 23.2

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We consent to the incorporation by reference in the Registration Statement on Form S-1 (Nos. 333-

231143 and 333-249319), Form S-3 (Nos. 333-244367, 333-252587 and 333-276746) and Form S-8

(Nos. 333-219158, 333-224785, 333-230592, 333-237480, 333-254659, 333-258717, 333-279049 and

333-276748) of our report dated April 7, 2025, with respect to the consolidated financial statements of

Rein Therapeutics, Inc. as of and for the year ended December 31, 2024, included in this Annual Report

on Form 10-K for the year ended December 31, 2025.

 

 

 

/s/ Marcum LLP

 

New York, New York

March 26, 2026

 

 

 

 

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer